HRP20120652T1 - Organski spojevi - Google Patents

Organski spojevi Download PDF

Info

Publication number
HRP20120652T1
HRP20120652T1 HRP20120652TT HRP20120652T HRP20120652T1 HR P20120652 T1 HRP20120652 T1 HR P20120652T1 HR P20120652T T HRP20120652T T HR P20120652TT HR P20120652 T HRP20120652 T HR P20120652T HR P20120652 T1 HRP20120652 T1 HR P20120652T1
Authority
HR
Croatia
Prior art keywords
staurosporine
benzoyl
crystalline form
solution
compound
Prior art date
Application number
HRP20120652TT
Other languages
English (en)
Croatian (hr)
Inventor
Hoehn Pascale
Koch Bernd
Mutz Michael
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35501294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120652(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20120652T1 publication Critical patent/HRP20120652T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
HRP20120652TT 2004-11-05 2005-11-03 Organski spojevi HRP20120652T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62534304P 2004-11-05 2004-11-05
US64213105P 2005-01-07 2005-01-07
PCT/EP2005/011789 WO2006048296A1 (fr) 2004-11-05 2005-11-03 Composes organiques

Publications (1)

Publication Number Publication Date
HRP20120652T1 true HRP20120652T1 (hr) 2012-09-30

Family

ID=35501294

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120652TT HRP20120652T1 (hr) 2004-11-05 2005-11-03 Organski spojevi

Country Status (31)

Country Link
US (2) US8198435B2 (fr)
EP (3) EP2955186A1 (fr)
JP (4) JP5057986B2 (fr)
KR (3) KR101265850B1 (fr)
CN (2) CN102627658A (fr)
AR (1) AR052322A1 (fr)
AU (2) AU2005300693B2 (fr)
BR (1) BRPI0517689A (fr)
CA (1) CA2584911C (fr)
CY (1) CY1113059T1 (fr)
DK (1) DK1812448T3 (fr)
EC (1) ECSP12007431A (fr)
ES (1) ES2388142T3 (fr)
GT (1) GT200500311A (fr)
HK (1) HK1211587A1 (fr)
HR (1) HRP20120652T1 (fr)
IL (3) IL182691A (fr)
JO (1) JO2897B1 (fr)
MA (1) MA29033B1 (fr)
MX (2) MX2007005429A (fr)
MY (2) MY154878A (fr)
NO (2) NO338960B1 (fr)
NZ (3) NZ554653A (fr)
PE (3) PE20130377A1 (fr)
PL (1) PL1812448T3 (fr)
PT (1) PT1812448E (fr)
RU (2) RU2394038C2 (fr)
SI (1) SI1812448T1 (fr)
TN (1) TNSN07165A1 (fr)
TW (4) TWI530500B (fr)
WO (1) WO2006048296A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
EP2327706A1 (fr) * 2009-11-30 2011-06-01 Novartis AG Formes polymorphiques III et IV de la N-benzoyl-staurosporine
KR20160008267A (ko) 2014-07-14 2016-01-22 주식회사 윈스 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템
US20200010481A1 (en) * 2017-03-06 2020-01-09 Teva Pharmaceutical Works Ltd. Solid state forms of midostaurin
WO2019215759A1 (fr) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad Procédé amélioré de préparation de midostaurine
IT201900004729A1 (it) 2019-03-29 2020-09-29 Procos Spa Processo per la preparazione di midostaurina ad elevato grado di purezza
WO2020261293A1 (fr) * 2019-06-24 2020-12-30 Dr. Reddy's Laboratories Limited Procédé de préparation de midostaurine
IT201900014346A1 (it) * 2019-08-08 2021-02-08 Procos Spa Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo
IT202000004291A1 (it) 2020-03-02 2021-09-02 Indena Spa Processo per la purificazione di alcaloidi indolo carbazolici
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
US20250387404A1 (en) * 2022-04-22 2025-12-25 Rutgers, The State University Of New Jersey Formulations and methods for treating epidermolysis bullosa simplex and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPS60185719A (ja) 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5073633A (en) * 1989-03-23 1991-12-17 Bristol-Myers Company BMY-41950 antitumor antibiotic
US5096330A (en) * 1990-06-21 1992-03-17 M-B-W Inc. Pitch control mechanism for a surface finishing machine
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
JPH05247955A (ja) 1992-03-06 1993-09-24 Taisei Corp 擁壁の施工方法
ES2136103T3 (es) 1992-06-22 1999-11-16 Kyowa Hakko Kogyo Kk Procedimiento para la preparacion de derivados de estaurosporina.
EP0763041A1 (fr) * 1994-06-01 1997-03-19 Novartis AG Derives d'indolocarbazole destines a sensibiliser a des agents antitumoraux des cellules a resistance multiple aux antitumoraux
RU2191175C2 (ru) 1995-12-11 2002-10-20 Сефалон, Инкорпорейтед Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с
CN1367789B (zh) * 1999-08-30 2012-06-06 波利弗尔股份公司 模板固定的β-发夹环模拟物的合成
DE60211494T2 (de) 2001-03-26 2006-10-12 Novartis Ag Pharmazeutische zusammensetzung enthaltend ein schlecht wasserlösliches staurosporin, eine oberflächenaktive substanz und ein wasserlösliches polymer
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
US7608420B2 (en) 2003-04-22 2009-10-27 Lonza Ag Process for the recovery of staurosporine from a fermentation broth

Also Published As

Publication number Publication date
AU2005300693B2 (en) 2010-08-19
US8710216B2 (en) 2014-04-29
PE20130377A1 (es) 2013-04-03
MY147404A (en) 2012-11-30
KR101265850B1 (ko) 2013-05-20
TW201247681A (en) 2012-12-01
MA29033B1 (fr) 2007-11-01
TNSN07165A1 (en) 2008-11-21
JP2015063569A (ja) 2015-04-09
EP2272850A2 (fr) 2011-01-12
PE20090433A1 (es) 2009-05-05
CY1113059T1 (el) 2016-04-13
PL1812448T3 (pl) 2012-10-31
BRPI0517689A (pt) 2008-10-14
MY154878A (en) 2015-08-14
NO20072290L (no) 2007-05-30
AU2005300693A1 (en) 2006-05-11
IL217571A (en) 2017-07-31
AR052322A1 (es) 2007-03-14
CA2584911C (fr) 2017-10-24
KR20120101600A (ko) 2012-09-13
TWI433852B (zh) 2014-04-11
IL207702A (en) 2016-09-29
TW200628474A (en) 2006-08-16
CN102627658A (zh) 2012-08-08
TWI530501B (zh) 2016-04-21
TWI530500B (zh) 2016-04-21
PT1812448E (pt) 2012-08-24
AU2009245817A1 (en) 2009-12-24
IL182691A (en) 2013-02-28
IL182691A0 (en) 2007-09-20
KR20120101601A (ko) 2012-09-13
HK1211587A1 (en) 2016-05-27
SI1812448T1 (sl) 2012-09-28
AU2009245817B2 (en) 2013-02-21
US20120322789A1 (en) 2012-12-20
WO2006048296A1 (fr) 2006-05-11
KR101289998B1 (ko) 2013-07-30
MX346525B (es) 2017-03-23
TW201247680A (en) 2012-12-01
JP2008518995A (ja) 2008-06-05
RU2467012C2 (ru) 2012-11-20
JP5057986B2 (ja) 2012-10-24
NZ588025A (en) 2012-04-27
EP2955186A1 (fr) 2015-12-16
KR20070083979A (ko) 2007-08-24
ECSP12007431A (es) 2012-06-29
EP2272850B1 (fr) 2017-05-10
JP2017061578A (ja) 2017-03-30
MX2007005429A (es) 2007-05-18
RU2009137788A (ru) 2011-04-20
TWI455941B (zh) 2014-10-11
CA2584911A1 (fr) 2006-05-11
RU2394038C2 (ru) 2010-07-10
NZ599033A (en) 2012-09-28
KR101333851B1 (ko) 2013-11-27
EP1812448A1 (fr) 2007-08-01
IL207702A0 (en) 2010-12-30
JP5701246B2 (ja) 2015-04-15
US20090137552A1 (en) 2009-05-28
NZ554653A (en) 2010-10-29
EP1812448B1 (fr) 2012-05-23
EP2272850A3 (fr) 2011-09-21
GT200500311A (es) 2006-05-22
NO340404B1 (no) 2017-04-18
US8198435B2 (en) 2012-06-12
CN102993213A (zh) 2013-03-27
NO20161152A1 (no) 2007-05-30
RU2007120695A (ru) 2008-12-10
HK1108881A1 (en) 2008-05-23
TW201446773A (zh) 2014-12-16
ES2388142T3 (es) 2012-10-09
PE20060947A1 (es) 2006-10-30
DK1812448T3 (da) 2012-08-27
JP2012149099A (ja) 2012-08-09
JO2897B1 (en) 2015-09-15
NO338960B1 (no) 2016-11-07

Similar Documents

Publication Publication Date Title
HRP20160246T4 (hr) Dimaleat od aminokrotonilskog spoja i postupak njegove proizvodnje
RU2008149242A (ru) Малеатный сокристалл azd1152
RU2009137788A (ru) Органические соединения
IL228220A (en) Tricyclic inhibitors of the gyrase enzyme
CA2700844A1 (fr) Compositions d'imatinib stables
CN105646584A (zh) 替诺福韦艾拉酚胺富马酸盐新晶型及其制备方法和用途
CN101362718A (zh) 4-(4-苯甲酰氨基苯氧基)-2-(甲基氨甲酰基)吡啶衍生物及其制备方法和用途
US20090275585A1 (en) Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition
EP2168964A4 (fr) Dérivés couplés d'azaindole et d'indole, procédés de préparation et utilisations
Mathew et al. Novel pyridopyrazine and pyrimidothiazine derivatives as FtsZ inhibitors
CN118125997B (zh) 紫檀芪丹皮酚查尔酮酰胺类衍生物、其制法及医药用途
WO2004005309A3 (fr) Substances anti-inflammatoires non steroidiennes, compositions et procedes d'utilisation de celles-ci
WO2022107745A1 (fr) Agent thérapeutique ou agent prophylactique contre la covid-19
WO2004111027A1 (fr) Derives isoflavoniques de tectoridine, preparation de ces derives et medicaments antiviraux contenant ces derives comme ingredients efficaces
CN105051034A (zh) 氮杂环丁烷基氧基苯基吡咯烷化合物
CN111423438A (zh) 具有抗肿瘤活性的Eudistomins Y类衍生物及其制备方法和应用
JPH06501944A (ja) Ｎ−（２−アルキル−３−メルカプトグルタリル）−アミノ−ジアザシクロアルカノン誘導体およびそれらのコラゲナーゼ抑制薬としての使用
WO2019031470A1 (fr) Nouveau composé à base d'amide, et inhibiteur de pin1, agent thérapeutique contre les maladies inflammatoires ainsi qu'agent thérapeutique contre le cancer mettant en œuvre celui-ci
CN102452986B (zh) N-甲酰羟胺类化合物及其制备方法和用途
CN102443005A (zh) 查尔酮的螺杂环类化合物及其用途
EP4119165A1 (fr) Nouveau composé d'acide 3,5-diaminobenzoïque, et inhibiteur de la pin1 et agent thérapeutique pour maladies inflammatoires le mettant en oeuvre
US20030120073A1 (en) Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases
CN102827116A (zh) 含α-芳基-γ-亚甲基丁烯内酯类化合物及其合成方法和用途
JPH06505229A (ja) 抗ウイルス薬としてのチアゾロ−［２，３−ａ］−イソインドール誘導体の使用および新規なチアゾロ−［２，３−ａ］−イソインドール誘導体
CN101602750B (zh) 萘基、（取代）芳基、哌嗪基脒类化合物